<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416403</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000522934</org_study_id>
    <secondary_id>UCSF-047522</secondary_id>
    <secondary_id>UCSF-H8409-26206-01</secondary_id>
    <secondary_id>MSKCC-06041</secondary_id>
    <nct_id>NCT00416403</nct_id>
  </id_info>
  <brief_title>Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer</brief_title>
  <official_title>Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the&#xD;
      laboratory may help doctors learn how fluvastatin effects biomarkers related to breast&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in&#xD;
      women undergoing surgery for ductal carcinoma in situ or stage I breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine differences between measures of cell proliferation (Ki-67) in women with&#xD;
           ductal carcinoma in situ (DCIS) or stage I breast cancer receiving neoadjuvant&#xD;
           fluvastatin sodium.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether statin use differentially affects specific types of DCIS/early-stage&#xD;
           breast cancer (comedo, estrogen receptor [ER]-positive, ER-negative).&#xD;
&#xD;
        -  Compare differences between tissue staining of CD68, circulating macrophages, and&#xD;
           regulatory T cells in these patients.&#xD;
&#xD;
        -  Assess the feasibility of using inherent susceptibility (mRNA polymerase chain reaction&#xD;
           testing) to predict response to statins in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, single-blind, multicenter, pilot study. Patients&#xD;
      are randomized to 1 of 2 treatment arms (arms I or II). Patients accrued as control&#xD;
      participants are assigned to arm III.&#xD;
&#xD;
        -  Arm I: Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral fluvastatin sodium as in arm I at a higher dose.&#xD;
&#xD;
        -  Arm III (control): Patients do not receive fluvastatin sodium. All patients then undergo&#xD;
           definitive surgery.&#xD;
&#xD;
      Patients in arms I and II undergo blood collection at baseline and at the time of surgery for&#xD;
      biomarker analysis. Patients in arm III undergo blood collection at baseline and then&#xD;
      approximately 1 month later. Tissue is collected from patients in all arms at the time of&#xD;
      surgery. Blood and tissue samples are examined for biological markers, including Ki-67,&#xD;
      C-reactive protein, cleaved caspase 3, HER2, CD68 gene, and estrogen and progesterone&#xD;
      receptors by immunohistochemistry. Markers of inflammation (e.g., comedo necrosis macrophages&#xD;
      and CD25-positive T cells), low-density lipoprotein, and cholesterol are also analyzed. Serum&#xD;
      mRNA is measured by polymerase chain reaction.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proliferation after statin exposure, as measured by Ki-67 level</measure>
    <time_frame>up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood and serum markers, including C-reactive protein, cleaved caspase 3, HER2, CD68, macrophages and immunoregulatory CD25 T cells, estrogen and progesterone receptors, mRNA, low-density lipoprotein, and cholesterol</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of comedo necrosis</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral fluvastatin sodium as in arm I at a higher dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients do not receive fluvastatin sodium. breast Cancer surgery only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluvastatin sodium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast Cancer Surgery Only - Arm III</intervention_name>
    <description>Breast Cancer Surgery</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ductal carcinoma in situ (DCIS) or stage I breast cancer by&#xD;
             stereotactic core or incisional biopsy&#xD;
&#xD;
          -  Planning to undergo surgery in 3-6 weeks&#xD;
&#xD;
               -  Patients undergoing re-excision due to evidence of tumor present at surgical&#xD;
                  margins are eligible&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ALT and AST â‰¤ 10% above upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to tolerate statins&#xD;
&#xD;
          -  Willing to undergo 2 blood draws (separated by approximately 3-4 weeks) during study&#xD;
             participation (control arm)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No other concurrent statins&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Niacin&#xD;
&#xD;
               -  Propranolol&#xD;
&#xD;
               -  Cholestyramine&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Digoxin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Gemfibrozil&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Diclofenac&#xD;
&#xD;
               -  Tolbutamide&#xD;
&#xD;
               -  Glyburide&#xD;
&#xD;
               -  Losartan&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Ranitidine&#xD;
&#xD;
               -  Omeprazole&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Warfarin&#xD;
&#xD;
          -  No initiation of new hormonal therapy during study participation&#xD;
&#xD;
          -  Concurrent participation in other clinical trials (e.g., for DCIS or prevention) is&#xD;
             allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura J. Esserman, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan;119(1):137-44. doi: 10.1007/s10549-009-0507-x.</citation>
    <PMID>19728082</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

